Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy

Yazhe Wang, Ying Xie, Jing Li, Zheng Hong Peng, Yuri Sheinin, Jianping Zhou, David Oupický

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Poor tumor penetration is a major challenge for the use of nanoparticles in anticancer therapy. Moreover, the inability to reach hypoxic tumor cells that are distant from blood vessels results in inadequate exposure to antitumor therapeutics and contributes to development of chemoresistance and increased metastasis. In the present study, we developed iRGD-modified nanoparticles for simultaneous tumor delivery of a photosensitizer indocyanine green (ICG) and hypoxia-activated prodrug tirapazamine (TPZ). The iRGD-modified nanoparticles loaded with ICG and TPZ showed significantly improved penetration in both 3D tumor spheroids in vitro and orthotopic breast tumors in vivo. ICG-mediated photodynamic therapy upon irradiation with a near-IR laser induced hypoxia, which activated antitumor activity of the codelivered TPZ for synergistic cell-killing effect. In vivo studies demonstrated that the nanoparticles could efficiently deliver the drug combination in 4T1 orthotopic tumors. Primary tumor growth and metastasis were effectively inhibited by the iRGD-modified combination nanoparticles with minimal side effects. The results also showed the anticancer benefits of codelivering ICG and TPZ in a single nanoparticle formulation in contrast to a mixture of nanoparticles containing individual drugs. The study demonstrates the benefits of combining tumor-penetrating nanoparticles with hypoxia-activated drug treatment and establishes a delivery platform for PDT and hypoxia-activated chemotherapy.

Original languageEnglish (US)
Pages (from-to)2227-2238
Number of pages12
JournalACS Nano
Volume11
Issue number2
DOIs
StatePublished - Feb 28 2017

Fingerprint

tirapazamine
hypoxia
Tumors
therapy
tumors
Nanoparticles
nanoparticles
Indocyanine Green
drugs
metastasis
delivery
penetration
Drug therapy
Photodynamic therapy
Photosensitizing Agents
Photosensitizers
Chemotherapy
blood vessels
spheroids
Blood vessels

Keywords

  • cancer
  • hypoxia
  • iRGD
  • nanoparticles
  • photodynamic therapy
  • tumor penetration

ASJC Scopus subject areas

  • Materials Science(all)
  • Engineering(all)
  • Physics and Astronomy(all)

Cite this

Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy. / Wang, Yazhe; Xie, Ying; Li, Jing; Peng, Zheng Hong; Sheinin, Yuri; Zhou, Jianping; Oupický, David.

In: ACS Nano, Vol. 11, No. 2, 28.02.2017, p. 2227-2238.

Research output: Contribution to journalArticle

Wang, Yazhe ; Xie, Ying ; Li, Jing ; Peng, Zheng Hong ; Sheinin, Yuri ; Zhou, Jianping ; Oupický, David. / Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy. In: ACS Nano. 2017 ; Vol. 11, No. 2. pp. 2227-2238.
@article{83ee763f87e54e079730d38d5da2bb03,
title = "Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy",
abstract = "Poor tumor penetration is a major challenge for the use of nanoparticles in anticancer therapy. Moreover, the inability to reach hypoxic tumor cells that are distant from blood vessels results in inadequate exposure to antitumor therapeutics and contributes to development of chemoresistance and increased metastasis. In the present study, we developed iRGD-modified nanoparticles for simultaneous tumor delivery of a photosensitizer indocyanine green (ICG) and hypoxia-activated prodrug tirapazamine (TPZ). The iRGD-modified nanoparticles loaded with ICG and TPZ showed significantly improved penetration in both 3D tumor spheroids in vitro and orthotopic breast tumors in vivo. ICG-mediated photodynamic therapy upon irradiation with a near-IR laser induced hypoxia, which activated antitumor activity of the codelivered TPZ for synergistic cell-killing effect. In vivo studies demonstrated that the nanoparticles could efficiently deliver the drug combination in 4T1 orthotopic tumors. Primary tumor growth and metastasis were effectively inhibited by the iRGD-modified combination nanoparticles with minimal side effects. The results also showed the anticancer benefits of codelivering ICG and TPZ in a single nanoparticle formulation in contrast to a mixture of nanoparticles containing individual drugs. The study demonstrates the benefits of combining tumor-penetrating nanoparticles with hypoxia-activated drug treatment and establishes a delivery platform for PDT and hypoxia-activated chemotherapy.",
keywords = "cancer, hypoxia, iRGD, nanoparticles, photodynamic therapy, tumor penetration",
author = "Yazhe Wang and Ying Xie and Jing Li and Peng, {Zheng Hong} and Yuri Sheinin and Jianping Zhou and David Oupick{\'y}",
year = "2017",
month = "2",
day = "28",
doi = "10.1021/acsnano.6b08731",
language = "English (US)",
volume = "11",
pages = "2227--2238",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy

AU - Wang, Yazhe

AU - Xie, Ying

AU - Li, Jing

AU - Peng, Zheng Hong

AU - Sheinin, Yuri

AU - Zhou, Jianping

AU - Oupický, David

PY - 2017/2/28

Y1 - 2017/2/28

N2 - Poor tumor penetration is a major challenge for the use of nanoparticles in anticancer therapy. Moreover, the inability to reach hypoxic tumor cells that are distant from blood vessels results in inadequate exposure to antitumor therapeutics and contributes to development of chemoresistance and increased metastasis. In the present study, we developed iRGD-modified nanoparticles for simultaneous tumor delivery of a photosensitizer indocyanine green (ICG) and hypoxia-activated prodrug tirapazamine (TPZ). The iRGD-modified nanoparticles loaded with ICG and TPZ showed significantly improved penetration in both 3D tumor spheroids in vitro and orthotopic breast tumors in vivo. ICG-mediated photodynamic therapy upon irradiation with a near-IR laser induced hypoxia, which activated antitumor activity of the codelivered TPZ for synergistic cell-killing effect. In vivo studies demonstrated that the nanoparticles could efficiently deliver the drug combination in 4T1 orthotopic tumors. Primary tumor growth and metastasis were effectively inhibited by the iRGD-modified combination nanoparticles with minimal side effects. The results also showed the anticancer benefits of codelivering ICG and TPZ in a single nanoparticle formulation in contrast to a mixture of nanoparticles containing individual drugs. The study demonstrates the benefits of combining tumor-penetrating nanoparticles with hypoxia-activated drug treatment and establishes a delivery platform for PDT and hypoxia-activated chemotherapy.

AB - Poor tumor penetration is a major challenge for the use of nanoparticles in anticancer therapy. Moreover, the inability to reach hypoxic tumor cells that are distant from blood vessels results in inadequate exposure to antitumor therapeutics and contributes to development of chemoresistance and increased metastasis. In the present study, we developed iRGD-modified nanoparticles for simultaneous tumor delivery of a photosensitizer indocyanine green (ICG) and hypoxia-activated prodrug tirapazamine (TPZ). The iRGD-modified nanoparticles loaded with ICG and TPZ showed significantly improved penetration in both 3D tumor spheroids in vitro and orthotopic breast tumors in vivo. ICG-mediated photodynamic therapy upon irradiation with a near-IR laser induced hypoxia, which activated antitumor activity of the codelivered TPZ for synergistic cell-killing effect. In vivo studies demonstrated that the nanoparticles could efficiently deliver the drug combination in 4T1 orthotopic tumors. Primary tumor growth and metastasis were effectively inhibited by the iRGD-modified combination nanoparticles with minimal side effects. The results also showed the anticancer benefits of codelivering ICG and TPZ in a single nanoparticle formulation in contrast to a mixture of nanoparticles containing individual drugs. The study demonstrates the benefits of combining tumor-penetrating nanoparticles with hypoxia-activated drug treatment and establishes a delivery platform for PDT and hypoxia-activated chemotherapy.

KW - cancer

KW - hypoxia

KW - iRGD

KW - nanoparticles

KW - photodynamic therapy

KW - tumor penetration

UR - http://www.scopus.com/inward/record.url?scp=85014157600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014157600&partnerID=8YFLogxK

U2 - 10.1021/acsnano.6b08731

DO - 10.1021/acsnano.6b08731

M3 - Article

C2 - 28165223

AN - SCOPUS:85014157600

VL - 11

SP - 2227

EP - 2238

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 2

ER -